Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE)
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose The association of dyslipidemia with stroke has been inconsistent, which may be due to differing associations within etiological stroke subtypes. We sought to determine the association of lipoproteins and apolipoproteins within stroke subtypes. Methods Standardized incident case-control STROKE study in 32 countries. Cases were patients with acute hospitalized first stroke, and matched by age, sex and site to controls. Concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (apoA1), and apoB were measured. Non-HDL-C was calculated. We estimated multivariable odds ratio (OR) and population attributable risk percentage (PAR%). Outcome measures were all stroke, ischemic stroke (and subtypes), and intracerebral hemorrhage (ICH). Results Our analysis included 11,898 matched case-control pairs; 77.3% with ischemic stroke and 22.7% with ICH. Increasing apoB (OR, 1.10; 95% confidence interval [CI], 1.06 to 1.14 per standard deviation [SD]) and LDL-C (OR, 1.06; 95% CI, 1.02 to 1.10 per SD) were associated with an increase in risk of ischemic stroke, but a reduced risk of ICH. Increased apoB was significantly associated with large vessel stroke (PAR 13.4%; 95% CI, 5.6 to 28.4) and stroke of undetermined cause. Higher HDL-C (OR, 0.75; 95% CI, 0.72 to 0.78 per SD) and apoA1 (OR, 0.63; 95% CI, 0.61 to 0.66 per SD) were associated with ischemic stroke (and subtypes). While increasing HDL-C was associated with an increased risk of ICH (OR, 1.20; 95% CI, 1.14 to 1.27 per SD), apoA1 was associated with a reduced risk (OR, 0.80; 95% CI, 0.75 to 0.85 per SD). ApoB/A1 (OR, 1.38; 95% CI, 1.32 to 1.44 per SD) had a stronger magnitude of association than the ratio of LDL-C/HDL-C (OR, 1.26; 95% CI, 1.21 to 1.31 per SD) with ischemic stroke (P<0.0001). Conclusions The pattern and magnitude of association of lipoproteins and apolipoproteins with stroke varies by etiological stroke subtype. While the directions of association for LDL, HDL, and apoB were opposing for ischemic stroke and ICH, apoA1 was associated with a reduction in both ischemic stroke and ICH. The ratio of apoB/A1 was the best lipid predictor of ischemic stroke risk.
Abstract
Background and Purpose The association of dyslipidemia with stroke has been inconsistent, which may be due to differing associations within etiological stroke subtypes. We sought to determine the association of lipoproteins and apolipoproteins within stroke subtypes. Methods Standardized incident case-control STROKE study in 32 countries. Cases were patients with acute hospitalized first stroke, and matched by age, sex and site to controls. Concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (apoA1), and apoB were measured. Non-HDL-C was calculated. We estimated multivariable odds ratio (OR) and population attributable risk percentage (PAR%). Outcome measures were all stroke, ischemic stroke (and subtypes), and intracerebral hemorrhage (ICH). Results Our analysis included 11,898 matched case-control pairs; 77.3% with ischemic stroke and 22.7% with ICH. Increasing apoB (OR, 1.10; 95% confidence interval [CI], 1.06 to 1.14 per standard deviation [SD]) and LDL-C (OR, 1.06; 95% CI, 1.02 to 1.10 per SD) were associated with an increase in risk of ischemic stroke, but a reduced risk of ICH. Increased apoB was significantly associated with large vessel stroke (PAR 13.4%; 95% CI, 5.6 to 28.4) and stroke of undetermined cause. Higher HDL-C (OR, 0.75; 95% CI, 0.72 to 0.78 per SD) and apoA1 (OR, 0.63; 95% CI, 0.61 to 0.66 per SD) were associated with ischemic stroke (and subtypes). While increasing HDL-C was associated with an increased risk of ICH (OR, 1.20; 95% CI, 1.14 to 1.27 per SD), apoA1 was associated with a reduced risk (OR, 0.80; 95% CI, 0.75 to 0.85 per SD). ApoB/A1 (OR, 1.38; 95% CI, 1.32 to 1.44 per SD) had a stronger magnitude of association than the ratio of LDL-C/HDL-C (OR, 1.26; 95% CI, 1.21 to 1.31 per SD) with ischemic stroke (P<0.0001). Conclusions The pattern and magnitude of association of lipoproteins and apolipoproteins with stroke varies by etiological stroke subtype. While the directions of association for LDL, HDL, and apoB were opposing for ischemic stroke and ICH, apoA1 was associated with a reduction in both ischemic stroke and ICH. The ratio of apoB/A1 was the best lipid predictor of ischemic stroke risk.
참고문헌 (57)
- Thrift AG, "Cholesterol is associated with stroke, but is not a risk factor", Stroke, 35, pp.1524~1525 (2004)
- Deedwania PC, "Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes", Int J Cardiol, 222, pp.548~556 (2016)
- van den Berg MJ, "Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B and cardiovascular risk in patients with manifest arterial disease", Am J Cardiol, 118, pp.804~810 (2016)
- Pérez de Isla L, "Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study)", Arterioscler Thromb Vasc Biol, 36, pp.2004~2010 (2016)
- Ito T, "Relationship between non-high-density lipoprotein cholesterol and the long-term mortality of cardiovascular diseases : NIPPON DATA 90", Int J Cardiol, 220, pp.262~267 (2016)
- Imamura T, "Non-high-density lipoprotein cholesterol and the development of coronary heart disease and stroke subtypes in a general Japanese population : the Hisayama Study", Atherosclerosis, 233, pp.343~348 (2014)
- Prospective Studies Collaboration, "Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths", Lancet, 370, pp.1829~1839 (2007)
- Holme I, "Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS)", J Intern Med, 265, pp.275~287 (2009)
- Emerging Risk Factors Collaboration, "Major lipids, apolipoproteins, and risk of vascular disease", JAMA, 302, pp.1993~2000 (2009)
- Emerging Risk Factors Collaboration, "The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases", Eur J Epidemiol, 22, pp.839~869 (2007)
- Chang JG, "Apolipoproteins for cardiovascular risk assessment", Am Fam Physician, 89, pp.662A~662B (2014)
- Ma Y, "Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage", Lipids Health Dis, 15, pp.43~ (2016)
- Lee JS, "Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status:the Strong Heart Study", Diabetes Care, 40, pp.529~537 (2017)
- Glasser SP, "What is the association of lipid levels and incident stroke", Int J Cardiol, 220, pp.890~894 (2016)
- Pikula A, "Lipid and lipoprotein measurements and the risk of ischemic vascular events : Framingham Study", Neurology, 84, pp.472~479 (2015)
- Wu J, "Non-highdensity lipoprotein cholesterol vs low-density lipoprotein cholesterol as a risk factor for ischemic stroke: a result from the Kailuan study", Neurol Res, 35, pp.505~511 (2013)
- Araki A, "Non-high-density lipoprotein cholesterol : an important predictor of stroke and diabetes-related mortality in Japanese elderly diabetic patients", Geriatr Gerontol Int, 12(Suppl 1), pp.18~28 (2012)
- Berger JS, "Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women", Stroke, 43, pp.958~966 (2012)
- Mora S, "Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study", Ann Intern Med, 155, pp.742~750 (2011)
- Yokokawa H, "Serum low-density lipoprotein to high-density lipoprotein ratio as a predictor of future acute myocardial infarction among men in a 2.7-year cohort study of a Japanese northern rural population", J Atheroscler Thromb, 18, pp.89~98 (2011)
- Willey JZ, "Lipid profile components and risk of ischemic stroke: the Northern Manhattan Study (NOMAS)", Arch Neurol, 66, pp.1400~1406 (2009)
- Kurth T, "Lipid levels and the risk of ischemic stroke in women", Neurology, 68, pp.556~562 (2007)
- Walldius G, "Stroke mortality and the apoB", apoA-I ratio : results of the AMORIS prospective study, 2006, pp.259, 259~266
- Wang X, "Cholesterol levels and risk of hemorrhagic stroke : a systematic review and meta-analysis", Stroke, 44, pp.1833~1839 (2013)
- Lv P, "Comparison of risk factor between lacunar stroke and large artery atherosclerosis stroke : a cross-sectional study in China", PLoS One, 11, pp.e0149605~ (2016)
- Kumral E, "Association of baseline dyslipidemia with stroke recurrence within five-years after ischemic stroke", Int J Stroke, 9(Suppl A100), pp.119~126 (2014)
- Laloux P, "Lipids in ischemic stroke subtypes", Acta Neurol Belg, 104, pp.13~19 (2004)
- Bang OY, "Association of serum lipid indices with large artery atherosclerotic stroke", Neurology, 70, pp.841~847 (2008)
- O’Donnell MJ, "Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE):a case-control study", Lancet, 388, pp.761~775 (2016)
- O’Donnell M, "Rationale and design of INTERSTROKE : a global case-control study of risk factors for stroke", Neuroepidemiology, 35, pp.36~44 (2010)
- Hatano S, "Experience from a multicentre stroke register : a preliminary report", Bull World Health Organ, 54, pp.541~553 (1976)
- Bamford J, "Classification and natural history of clinically identifiable subtypes of cerebral infarction", Lancet, 337, pp.1521~1526 (1991)
- Adams HP Jr, "Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
- Aerden L, "Validation of the Oxfordshire Community Stroke Project syndrome diagnosis derived from a standard symptom list in acute stroke", J Neurol Sci, 220, pp.55~58 (2004)
- Mead GE, "How well does the Oxfordshire community stroke project classification predict the site and size of the infarct on brain imaging", J Neurol Neurosurg Psychiatry, 68, pp.558~562 (2000)
- Bonita R, "Recovery of motor function after stroke", Stroke, 19, pp.1497~1500 (1988)
- Yusuf S, "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study", Lancet, 364, pp.937~952 (2004)
- Benichou J, "Variance calculations and confidence intervals for estimates of the attributable risk based on logistic models", Biometrics, 46, pp.991~1003 (1990)
- Hindy G, "Role of blood lipids in the development of ischemic stroke and its subtypes : a Mendelian Randomization Study", Stroke, 49, pp.820~827 (2018)
- Hosomi N, "The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study", EBioMedicine, 2, pp.1071~1078 (2015)
- Amarenco P, "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 355, pp.549~559 (2006)
- Amarenco P, "A comparison of two LDL cholesterol targets after ischemic stroke", N Engl J Med, 382, pp.9~ (2020)
- Yusuf S, "Cholesterol lowering in intermediate-risk persons without cardiovascular disease", N Engl J Med, 374, pp.2021~2031 (2016)
- Bhatia M, "Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack", Cerebrovasc Dis, 21, pp.323~328 (2006)
- Holmes MV, "Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke", J Am Coll Cardiol, 71, pp.620~632 (2018)
- Longstreth WT Jr, "Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study", Stroke, 36, pp.56~61 (2005)
- Vernooij MW, "Prevalence and risk factors of cerebral microbleeds : the Rotterdam Scan Study", Neurology, 70, pp.1208~1214 (2008)
- Collins R, "Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions", Lancet, 363, pp.757~767 (2004)
- Allara E, "Genetic determinants of lipids and cardiovascular disease outcomes : a wide-angled Mendelian randomization investigation", Circ Genom Precis Med, 12, pp.e002711~ (2019)
- Ko DT, "High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions : the CANHEART Study", J Am Coll Cardiol, 68, pp.2073~2083 (2016)
- Boyce G, "The pleiotropic vasoprotective functions of high density lipoproteins (HDL)", J Biomed Res, 32, pp.164~182 (2017)
- Button EB, "ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP", PS1 mice, 2019, pp.11, 44~
- Anderson CD, "Genetic variants in CETP increase risk of intracerebral hemorrhage", Ann Neurol, 80, pp.730~740 (2016)
- Rhee EJ, "The HDL cholesterol", apolipoprotein A-I ratio : an indicator of cardiovascular disease, 2017, pp.24, 148~153
- Barter PJ, "Effects of torcetrapib in patients at high risk for coronary events", N Engl J Med, 357, pp.2109~2122 (2007)
- Brunner FJ, "Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium", Lancet, 394, pp.2173~2183 (2019)
- Mortensen MB, "Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years : a contemporary primary prevention cohort", Lancet, 396, pp.1644~1652 (2020)